0000929638-16-001287.txt : 20160226 0000929638-16-001287.hdr.sgml : 20160226 20160226160604 ACCESSION NUMBER: 0000929638-16-001287 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20160226 DATE AS OF CHANGE: 20160226 GROUP MEMBERS: BIHUA CHEN GROUP MEMBERS: CORMORANT ASSET MANAGEMENT, LLC GROUP MEMBERS: CORMORANT GLOBAL HEALTHCARE GP, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-89403 FILM NUMBER: 161461689 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-225-0096 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Cormorant Global Healthcare Master Fund, LP CENTRAL INDEX KEY: 0001618442 IRS NUMBER: 981101801 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: 52ND FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-848-3429 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: 52ND FLOOR CITY: BOSTON STATE: MA ZIP: 02116 SC 13G 1 cormorant13g.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number:3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response… 10.4

 
SCHEDULE 13G
 
  
 
Under the Securities Exchange Act of 1934
 
  
 
(Amendment No. ___)*
  

 
Proteostasis Therapeutics, Inc.
  
 
(Name of Issuer)
  

 
Common Stock, par value $0.001 per share
  
 
(Title of Class of Securities)
  

 
74373B109
  
 
(CUSIP Number)
  

 
February 16, 2016
  
 
(Date of Event which Requires Filing of this Statement)
  


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]            Rule 13d-1(b)
[x]            Rule 13d-1(c)
[ ]            Rule 13d-1(d)
___________________________________
*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
1
 
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
 
Cormorant Global Healthcare Master Fund, LP
 
 
2
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
 
(a)            [ ]
 
 
(b)            [x]
 
3
 
SEC Use Only
 
4
 
Citizenship or Place of Organization.
 
Cayman Islands
 
 
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
 
5  Sole Voting Power
 
0 shares
 
 
6  Shared Voting Power
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
7  Sole Dispositive Power
 
0 shares
 
 
8  Shared Dispositive Power
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
9
 
Aggregate Amount Beneficially Owned by Each Reporting Person
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
Refer to Item 4 below.
  
 
10
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ] N/A
  
 
11
 
Percent of Class Represented by Amount in Row (9)*
 
7.6% (7.7% as of February 26, 2016)
 
Refer to Item 4 below.
  
 
12
 
Type of Reporting Person (See Instructions)
 
PN (Partnership)
 
  


 
1
 
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
 
Cormorant Global Healthcare GP, LLC
 
 
2
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
 
(a)            [ ]
 
 
(b)            [x]
 
3
 
SEC Use Only
 
4
 
Citizenship or Place of Organization.
 
Delaware
 
 
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
 
5  Sole Voting Power
 
0 shares
 
 
6  Shared Voting Power
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
 
Refer to Item 4 below.
 
7  Sole Dispositive Power
 
0 shares
 
 
8  Shared Dispositive Power
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
 
Refer to Item 4 below.
 
9
 
Aggregate Amount Beneficially Owned by Each Reporting Person
 
1,450,825 shares (1,466,734 shares as of February 26, 2016)
 
 
Refer to Item 4 below.
  
 
10
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ] N/A
  
 
11
 
Percent of Class Represented by Amount in Row (9)*
 
7.6% (7.7% as of February 26, 2016)
 
Refer to Item 4 below.
  
 
12
 
Type of Reporting Person (See Instructions)
 
OO (Limited Liability Company)
 
  


 
1
 
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
 
Cormorant Asset Management, LLC
 
 
2
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
 
(a)            [ ]
 
 
(b)            [x]
 
3
 
SEC Use Only
 
4
 
Citizenship or Place of Organization.
 
Delaware
 
 
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
 
5  Sole Voting Power
 
0 shares
 
 
6  Shared Voting Power
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
7  Sole Dispositive Power
 
0 shares
 
 
8  Shared Dispositive Power
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
9
 
Aggregate Amount Beneficially Owned by Each Reporting Person
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
  
 
10
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ] N/A
  
 
11
 
Percent of Class Represented by Amount in Row (9)*
 
9.0% (9.1% as of February 26, 2016)
 
Refer to Item 4 below.
  
 
12
 
Type of Reporting Person (See Instructions)
 
OO (Limited Liability Company)
 
  


 
1
 
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
 
Bihua Chen
 
 
2
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
 
(a)            [ ]
 
 
(b)            [x]
 
3
 
SEC Use Only
 
4
 
Citizenship or Place of Organization.
 
United States
 
 
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
 
5  Sole Voting Power
 
0 shares
 
 
6  Shared Voting Power
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
7  Sole Dispositive Power
 
0 shares
 
 
8  Shared Dispositive Power
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
 
9
 
Aggregate Amount Beneficially Owned by Each Reporting Person
 
1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
Refer to Item 4 below.
  
 
10
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ] N/A
  
 
11
 
Percent of Class Represented by Amount in Row (9)*
 
9.0% (9.1% as of February 26, 2016)
 
Refer to Item 4 below.
  
 
12
 
Type of Reporting Person (See Instructions)
 
IN (Individual)
 
  

Item 1.

(a)
Name of Issuer
 
 
Proteostasis Therapeutics, Inc.
 
(b)
Address of Issuer’s Principal Executive Offices
 
 
200 Technology Square, 4th Floor
Cambridge, Massachusetts 02139

Item 2.

(a)
Name of Person Filing
 
 
Cormorant Global Healthcare Master Fund, LP
Cormorant Global Healthcare GP, LLC
Cormorant Asset Management, LLC
Bihua Chen
  
(b)
Address of Principal Business Office or, if none, Residence
 
 
200 Clarendon Street, 52nd Floor
Boston, MA 02116
 
(c)
Citizenship
 
 
Cormorant Global Healthcare Master Fund, LP - Cayman Islands
Cormorant Global Healthcare GP, LLC - Delaware
Cormorant Asset Management, LLC - Delaware
 Bihua Chen - United States
 
(d)
Title of Class of Securities
 
 
Common Stock
 
(e)
CUSIP Number
 
74373B109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)
 
[ ]
 
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
 
(b)
 
[ ]
 
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
 
(c)
 
[ ]
 
Insurance Company as defined in Section 3(a)(19) of the Act
 
(d)
 
[ ]
 
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 
(e)
 
[ ]
 
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
(f)
 
[ ]
 
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
(g)
 
[ ]
 
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
 
(h)
 
[ ]
 
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
(i)
 
[ ]
 
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
(j)
 
[ ]
 
A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
 
(k)
 
[ ]
 
Group, in accordance with §240.13d-1(b)(1)(ii)(K).
 

Item 4. Ownership***
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)
Amount Beneficially Owned***
 
 
Cormorant Global Healthcare Master Fund, LP – 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Global Healthcare GP, LLC - 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Asset Management, LLC - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 Bihua Chen - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
(b)
Percent of Class
 
Cormorant Global Healthcare Master Fund, LP – 7.6% (7.7% as of February 26, 2016)
Cormorant Global Healthcare GP, LLC - 7.6% (7.7% as of February 26, 2016)
Cormorant Asset Management, LLC - 9.0% (9.1% as of February 26, 2016)
 Bihua Chen - 9.0% (9.1% as of February 26, 2016)
 
(c)
Number of shares as to which such person has:
 
 
(i)
sole power to vote or to direct the vote
   
 
Cormorant Global Healthcare Master Fund, LP - 0 shares
 Cormorant Global Healthcare GP, LLC - 0 shares
Cormorant Asset Management, LLC - 0 shares
Bihua Chen - 0 shares
 
 
(ii)
shared power to vote or to direct the vote
   
 
Cormorant Global Healthcare Master Fund, LP – 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Global Healthcare GP, LLC - 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Asset Management, LLC - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 Bihua Chen - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
 
(iii)
sole power to dispose or to direct the disposition of
 
   
Cormorant Global Healthcare Master Fund, LP – 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Global Healthcare GP, LLC - 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Asset Management, LLC - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 Bihua Chen - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 
 
(iv)
shared power to dispose or to direct the disposition of
   
 
Cormorant Global Healthcare Master Fund, LP – 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Global Healthcare GP, LLC - 1,450,825 shares (1,466,734 shares as of February 26, 2016)
Cormorant Asset Management, LLC - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 Bihua Chen - 1,725,460 shares (1,744,399 shares as of February 26, 2016)
 

*** Shares reported herein for Cormorant Asset Management, LLC represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Fund”), as reported herein, and shares which are beneficially owned by a managed account (the “Account”).  Cormorant Global Healthcare GP, LLC serves as the general partner of the Fund, and Cormorant Asset Management, LLC serves as the investment manager to both the Fund and the Account.  Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and Cormorant Asset Management, LLC.  Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
February 26, 2016

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
 its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

/s/ Bihua Chen
Bihua Chen
 EX-1 2 exhibit1.htm
Exhibit 1
 
JOINT FILING AGREEMENT
This Joint Filing Agreement, dated as of February 26, 2016, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen (collectively, the “Filers”).
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Proteostasis Therapeutics, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.


CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
By: Cormorant Global Healthcare GP, LLC
its General Partner

By: /s/ Bihua Chen                                                                            
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: /s/ Bihua Chen                                                                            
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LLC

By: /s/ Bihua Chen                                                                            
Bihua Chen, Managing Member

/s/ Bihua Chen                                                              
Bihua Chen